Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

BACKGROUND: The median age of newly diagnosed patients with non-small cell lung cancer (NSCLC) is 67 years, and one-third of patients are older than 75 years. Elderly patients are more vulnerable to the adverse effects of chemotherapy, and targeted therapy might thus be a relevant alternative. The o...

Descripción completa

Detalles Bibliográficos
Autores principales: Christos, Chouaid, Hervé, Le Caer, Chrystelle, Locher, Cecile, Dujon, Pascal, Thomas, Jean Bernard, Auliac, Isabelle, Monnet, Alain, Vergnenegre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492214/
https://www.ncbi.nlm.nih.gov/pubmed/22817667
http://dx.doi.org/10.1186/1471-2407-12-301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492214/
https://www.ncbi.nlm.nih.gov/pubmed/22817667
http://dx.doi.org/10.1186/1471-2407-12-301

Ejemplares similares